RT Journal Article
SR Electronic
T1 Using Machine-Learning for Prediction of the Response to Cardiac Resynchronization Therapy: the SMART-AV Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.16.20155424
DO 10.1101/2020.07.16.20155424
A1 Howell, Stacey J.
A1 Stivland, Tim
A1 Stein, Kenneth
A1 Ellenbogen, Kenneth A.
A1 Tereshchenko, Larisa G.
YR 2020
UL http://medrxiv.org/content/early/2020/07/18/2020.07.16.20155424.abstract
AB Background There is a controversy whether the response of both sexes to cardiac resynchronization therapy (CRT) is similar. Optimal CRT delivery requires procedure planning.Objective To apply machine learning (ML) to develop a prediction model for CRT response.Methods Participants from the SmartDelay Determined AV Optimization (SMART-AV) trial (n=741; age, 66 ±11 yrs; 33% female; 100% NYHA III-IV; 100% EF≤35%) were randomly split into training & testing (80%; n=593), and validation (20%; n=148) samples. The entropy balancing procedure was used to match for the means of 30 covariates in male and female groups. Baseline clinical, ECG, echocardiographic and biomarker characteristics, and left ventricular (LV) lead position (43 variables) were included in 6 ML models (random forests, convolutional neural network, lasso, adaptive lasso, plugin lasso, elastic net, ridge, and logistic regression). A composite of freedom from death and heart failure hospitalization and a >15% reduction in LV end-systolic volume index at 6-months post-CRT was the endpoint.Results The primary endpoint was met by 337 patients (45.5%). Weighting resulted in a perfect balance of means of covariates in men and women. After reweighting, CRT response for women versus men was similar (OR 1.53; 95%CI 0.88-2.65; P=0.131). The adaptive lasso model was more accurate than class I ACC/AHA guidelines criteria (AUC 0.759; 95%CI 0.678-0.840 versus 0.639; 95%CI 0.554-0.722; P<0.0001), well-calibrated, and parsimonious (19 predictors; nearly half are potentially modifiable).Conclusions After balancing for covariates, both sexes similarly benefit from CRT. ML predicts short-term CRT response and thus may help with CRT procedure planning.Competing Interest StatementSMART AV was sponsored by Boston Scientific. Two co-authors are Boston Scientific employees. The current work was not sponsored by Boston Scientific. Boston Scientific had no role in the design of this study and had no any role during its execution, analyses, interpretation of the data, or decision to submit results.Clinical TrialClinicalTrials.gov Identifier: NCT00677014Funding StatementSMART AV randomized controlled trial was sponsored by Boston Scientific.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Oregon Health & Science University Institutional Review Board reviewed the current study and determined the deidentified nature of the dataset.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe provided open-source code for statistical data analysis at https://github.com/Tereshchenkolab/statistics.AVatrioventricularACEI/ARBangiotensin converting enzyme inhibitor or angiotensin II receptor blockerCMcardiomyopathyCRTcardiac resynchronization therapyEFejection fractionHFheart failureLBBBleft bundle branch blockLVleft ventricularMLmachine learningNYHANew York Heart AssociationSMART-AVSmartDelay Determined Atrioventricular OptimizationRCTrandomized controlled trialBSAbody surface areaORodds ratio